Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group

Autor: Abrams, D, Allan, D, Antunes, F, Breckenridge, A, Bruun, J, Cameron, W, Carbon, C, Chalmers, I, Chang, H, Chodakewitz, J, Clendenin, N, Clumeck, N, Collier, A, Collins, G, Cooper, E, Cooper, D, Danner, S, D'Aquila, R, DeGruttola, V, DeMasi, R, Dee, L, Deyton, L, Dixon, D, Farthing, C, Feinberg, J, Fischl, M, Flepp, M, Gartland, M, Gatell, J, Gazzard, B, Goebel, F, Gotzsche, P, Gringeri, A, Hall, D, Hamilton, J, Hammer, S, Hartigan, P, Heath-Chiozzi, M, Henry, K, Hill, A, Hirschel, B, Ioannidis, J, Kahn, J, Katlama, C, Katzenstein, D, Killen, J, King, E, de Loes, SK, Kravcik, S, Lange, J, Leavitt, R, Leonard, J, Maeland, A, Mannucci, P, Mathiesen, L, McDade, H, Meibohn, A, Melander, H, Merigan, T, Mulder, J, Myers, M, Neaton, J, Nessling, M, Perrin, L, Pettinelli, C, Phair, J, Phillips, A, Pinching, A, Poppa, A, Power, L, Reiss, P, Richman, D, Rooney, J, Rousseau, F, Rutherford, G, Salgo, M, Sandstrom, E, Saravolatz, L, Savidge, G, Schnittman, S, Schooley, R, Seligmann, M, Simberkoff, M, Skowron, G, Slade, P, Smith, D, Smith, RP, Soriano, V, Stanley, K, Stingl, G, Stoffels, P, Struthers, L, Tierney, C, Thompson, M, Van der Broeck, R, Van Leeuven, R, Van Weverling, G, Veenstra, J, Vella, S, Volberding, P, Weber, J, Winslow, D, Yeni, P, Yeo, J, Dormont, J, Sande, M, Weller, I, Babiker, A, Collins, R, Darbyshire, J, Duncan, W, Foulkes, M, Hughes, M, Peto, R, Peto, T, Walker, S, Grp, HIVTC
Jazyk: angličtina
Rok vydání: 1999
Zdroj: Lancet. 353(9169)
ISSN: 1474-547X
0140-6736
Popis: BACKGROUND: To assess the effects of zidovudine, didanosine, and zalcitabine on HIV disease progression and survival, we undertook meta-analyses of individual patient data and tabular data from all randomised trials that compared these agents. METHODS: Individual patient data were available for 7722 participants without AIDS in the nine randomised trials of immediate versus deferred zidovudine, and 7700 participants with or without AIDS in the six trials comparing zidovudine plus didanosine, zidovudine plus zalcitabine, or zidovudine alone. The main outcomes were mortality and disease progression (new AIDS-defining event or death before any such event). FINDINGS: In the comparison of immediate versus deferred zidovudine, during a median follow-up of 50 months, 1908 individuals progressed, of whom 1351 died. In the deferred group, 61% started antiretroviral therapy (median time to therapy 28 months, which was zidovudine monotherapy in 94%). During the first year of follow-up, immediate zidovudine halved the rate of disease progression (p
Databáze: OpenAIRE
Externí odkaz: